Better patient outcomes with drug eluting stents

December 18, 2008

Patients receiving drug eluting stents (DES) -- stents coated with medication to prevent narrowing of the artery -- as part of an angioplasty had better outcomes one year later than patients with bare metal stents, according to a new study to be published in CMAJhttp://www.cmaj.ca/press/080050.pdf.

Mortality in the first 30 days for people with drug eluting stents was significantly lower than for those with bare metal stents. However, in this prospective cohort study of 6440 patients, there was an increased risk of repeat revascularization procedures or death in the DES group after 3 years.

Patients with drug eluting stents were more likely to be female, with higher rates of kidney disease, diabetes, high cholesterol and hypertension.

"Our study findings suggest that drug eluting stents, despite recent concerns surrounding drug eluting stent safety, the long-term survival (to 3 years) of patients receiving drug eluting stents remains globally favourable, and certainly not measurably worse than that of patients treated with bare metal stents," state Dr. William Ghali, coauthors from the University of Calgary and Dr. Andrew Philpott. "However, we did observe a concerning risk trend toward accelerating adverse events in the DES group late in the follow-up period -- a finding that underlines the need for ongoing surveillance of longer-term outcomes," write the authors.

Visit cmaj.ca later this week for a related commentary by Dr. Philippe Généreux and Dr. Roxana Mehran from the Columbia University Medical Center. They also caution that "despite the large amount of favourable long-term data on the use of drug eluting stents from randomized controlled trials, meta-analyses and observational studies, the long-term safety of drug eluting stents, especially regarding late and very late stent thrombosis, remains a major concern."
-end-
About CMAJ

CMAJ showcases innovative research and ideas aimed at improving health for people in Canada and globally. It publishes original clinical research, analyses and reviews, news, practice updates and editorials. CMAJ.ca, a full-text, free open-access website, allows everyone to use the latest health information. CMAJ has an impact factor of 7.1 and its website receives over 25 million requests a year. Visit www.cmaj.ca for medical knowledge that matters.

Canadian Medical Association Journal

Related Drug Eluting Stents Articles from Brightsurf:

Oncotarget: Sirolimus-eluting stents -- opposite in vitro effects on the clonogenic cell potential
The cover for issue 31 of Oncotarget features Figure 4, ''Concentration dose-response curves of sirolimus effect [55 nM-1 nM] on the number of cells per surviving colony in U2OS cell line after 2 weeks exposure,'' by Vasuri, et al. which reported that the authors evaluated the long-term effects of sirolimus on three different cell in vitro models, cultured in physiological conditions mimicking sirolimus-eluted stent, in order to clarify the effectiveness of sirolimus in blocking cell proliferation and survival.

Fighting bacterial infection with drug-eluting medical devices
Medical practitioners routinely outfit patients with devices ranging from cardiovascular stents, pacemakers, catheters, and therapeutic lenses to orthopedic, breast, dental, and cochlear implants and prostheses.

Novel drug-eluting stent with improved radiographic visibility found to be safe and effective
This first randomized clinical study of a polymer-coated zotarolimus-eluting stent (Resolute Onyx) that utilizes a novel thin-strutted metallic platform allowing for better x-ray visibility was shown to be non-inferior to an ultrathin-strutted bioresorbable polymer-coated sirolimus-eluting stent (Orsiro) that uses a cobalt-chromium strut platform.

New clinical trial shows second generation drug-eluting stents are safe and effective
Results of the PERSPECTIVE trial were presented today as late-breaking clinical science at the SCAI 2018 Scientific Sessions, and reports on one-year outcomes of patients undergoing CTO PCI treated with Zotarolimus-Eluting Stents (ZES).

BASKET-SAVAGE trial: Drug-eluting stents more benefit in saphenous vein grafts
Drug-eluting stents had a clear advantage over bare metal stents in patients undergoing revascularization of saphenous (leg) vein grafts, results of the BASKET-SAVAGE trial show.

Less efficacy than expected in largest drug-eluting stent trial
New generation drug-eluting stents did not outshine contemporary bare metal stents as they were expected to, in a surprise finding of the largest randomized stent trial to date.

Antibody-coated drug-eluting stents for coronary heart disease: No hint of benefit
Due to a lack of suitable data, in patients with coronary heart disease the benefit of antibody-coated drug-eluting stents versus drug-eluting stents without antibody coating is unclear.

No mortality benefit of bypass surgery compared to latest generation of drug-coated stents
Newer drug-coated stents that keep arteries open have similar long-term rates of death compared with traditional bypass surgery for patients with more than one diseased coronary artery.

Big data study identifies new potential target coating for drug-eluting stents
A new study has identified an FDA approved cancer drug, crizotinib, as a possible new coating for drug-eluting stents.

Intracranial stents: More strokes than with drug treatment alone
Patients who, after a stroke, not only receive medications, but also stent implantation in their blood vessels in the brain, have another stroke considerably more often.

Read More: Drug Eluting Stents News and Drug Eluting Stents Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.